IL-2-based immunotherapy alters circulating neutrophil Fc receptor expression and chemotaxis
- PMID: 2158514
IL-2-based immunotherapy alters circulating neutrophil Fc receptor expression and chemotaxis
Abstract
We performed functional assays on polymorphonuclear (PMN) leukocytes from 21 patients with advanced cancers, before, during, and after IL-2 administration. Of these, 19 were treated with high dose bolus IL-2 infusions (10(5) U/kg every 8 h) and 2 patients received low dose continuous infusions of IL-2 (250 U/kg/h). Five of six patients studied after IL-2 therapy had a decrease in their PMN chemotactic response to FMLP after bolus IL-2 (mean 8 doses) or, after the 4th day of continuous infusion IL-2 (pre-IL-2 values of 82% +/- 17% to 45% +/- 1% post-IL-2, p2 less than 0.004) compared with normal control values. In 8 of 10 patients studied, PMN capacity to oxidize intracellular dichlorofluorescein dye, an indirect measurement of O2- production in response to PMA stimulation, decreased after IL-2 administration (pre-IL-2 mean dichlorofluorescein oxidation (by channel number) 243 +/- 128 vs 3-day post-IL-2 87 +/- 86, p2 less than 0.02). Furthermore, a marked decrease in Fc gamma R III (Leu-11, CD16) expression was observed in 12/13 patients' PMN studied after IL-2 therapy (mean percent of PMN population with positive FcR expression was 81.1 +/- 15.4% pre-IL-2 which decreased to 56.0 +/- 30.5% post-IL-2, p2 less than 0.001). Other PMN surface markers (My4, My7, ICAM-1, LFA1, LFA3, Mac1) did not change significantly. PMN-mediated antibody-dependent cellular cytotoxicity did not change after IL-2 therapy (only 4/15 patients demonstrated more than 50% reduction in antibody-dependent cellular cytotoxicity). PMN phagocytosis of Staphylococcus aureus was also not significantly altered by IL-2 administration in six patients studied (pre-IL-2, 99 +/- 17% vs 111 +/- 28% post-IL-2, p2 greater than 0.2). We conclude that the systemic administration of IL-2 by intermittent or continuous administration is associated with marked changes in PMN function and cell surface receptor expression. These alterations may contribute to the apparent increased susceptibility to bacterial infection observed in these patients.
Similar articles
-
Monokines released during short-term Fc gamma receptor phagocytosis up-regulate polymorphonuclear leukocytes and monocyte-phagocytic function.J Immunol. 1991 Jul 1;147(1):265-72. J Immunol. 1991. PMID: 1828823
-
Alterations in chemotactic factor-induced responses of neutrophils and monocytes from chronic dialysis patients.Clin Nephrol. 1988 Aug;30(2):63-72. Clin Nephrol. 1988. PMID: 2846218
-
Fc gamma receptor-mediated functions in neutrophils are modulated by adenosine receptor occupancy. A1 receptors are stimulatory and A2 receptors are inhibitory.J Immunol. 1990 Oct 1;145(7):2235-40. J Immunol. 1990. PMID: 2168919
-
Physiological studies with human leukocyte inhibitory factor.Immunol Ser. 1992;57:373-85. Immunol Ser. 1992. PMID: 1504141 Review.
-
Fc gamma receptor mediated activation of human polymorphonuclear neutrophils (PMN).Arch Immunol Ther Exp (Warsz). 1992;40(1):65-6. Arch Immunol Ther Exp (Warsz). 1992. PMID: 1485829 Review. No abstract available.
Cited by
-
Effect of culture media on lymphokine-activated killer effector phenotype and lytic capacity.Cancer Immunol Immunother. 1991;33(2):103-8. doi: 10.1007/BF01742537. Cancer Immunol Immunother. 1991. PMID: 2036657 Free PMC article.
-
Systemic administration of interleukin-2 inhibits inflammatory neutrophil migration: role of nitric oxide.Br J Pharmacol. 2006 Aug;148(8):1060-6. doi: 10.1038/sj.bjp.0706835. Epub 2006 Jul 24. Br J Pharmacol. 2006. PMID: 16865093 Free PMC article.
-
The immunobiological effects of interleukin-2 in vivo.Cancer Immunol Immunother. 1994 Oct;39(4):207-16. doi: 10.1007/BF01525983. Cancer Immunol Immunother. 1994. PMID: 7954522 Free PMC article. Review. No abstract available.
-
On-chip evaluation of neutrophil activation and neutrophil-endothelial cell interaction during neutrophil chemotaxis.Anal Chem. 2013 Nov 19;85(22):10787-96. doi: 10.1021/ac4020098. Epub 2013 Oct 28. Anal Chem. 2013. PMID: 24127752 Free PMC article.
-
Totally implanted catheters to reduce catheter-related infections in patients receiving interleukin-2: a 2-year experience.Support Care Cancer. 1995 Sep;3(5):297-300. doi: 10.1007/BF00335305. Support Care Cancer. 1995. PMID: 8520875 Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Miscellaneous